ESTRO 2024 - Abstract Book

S404

Brachytherapy - Urology

ESTRO 2024

Purpose/Objective:

Brachytherapy (BT) is a standard treatment for low- and favorable intermediate-risk prostate adenocarcinoma. Few studies have focused on young patients. We therefore evaluated long-term efficacy and toxicity of BT in patients aged under 60 years with low- and favorable intermediate-risk prostate cancer.

Material/Methods:

This retrospective study included patients aged under 60 years with low- or favorable intermediate-risk prostate adenocarcinoma treated with iodine BT alone between 1999-2014 at the Institut de Cancérologie de Lorraine. Follow-up assessment included incidence of biochemical failure (BF) at 10 and 15 years after BT, as well as survival data and late toxicities.

Results:

A total of 177 patients of median age 56 years (54-58) were analyzed, with a median follow-up of 126 months (97 172). Incidence of BF at 10 and 15 years after BT was 5.4% and 11.7% respectively. PSA nadir (HR = 51.8 [95% CI 6.69 – 277], p < 0.001), age at treatment (HR = 1.78 [95% CI 1.19 – 2.65], p = 0.005) and prostate D90% (HR = 1.08 [95% CI 1.01 – 1.15], p < 0.021) were identified as predictive factors of BF. Overall survival at 10 and 15 years after BT was 92.8 % and 84,4% respectively. Cancer-specific survival at 10 and 15 years after BT was 99.3% and 97.7% respectively. No major toxicity was recorded.

Conclusion:

Exclusive BT is a long-term effective treatment for patients aged under 60 years with low- or favorable intermediate risk prostate adenocarcinoma.

Keywords: Young, biochemical failure, favorable prognosis

1069

Digital Poster

Prospective trial with hemiglandular brachytherapy in low-risk prostate cancer: a negative study.

Cristina Gutiérrez Miguélez 1 , Elena Villafranca 2 , Amaya Sola 2 , Andrea Slocker Escarpa 1 , Ignacio Visus 2 , Franciso Pino Sorroche 3 , Ruth Gracia Lucio 3 , Marta Barrado 2 , Montserrat Ventura Bujalance 4 , Margarita Illas 2 , Dina Najjari Jamal 1 , Naiara Fuentemilla 5 , Pilar Fernández López 1 , Santiago Pellejero 5 , Ferran Guedea Edo 4 , Nuria Gómez Martínez 6 1 Institut Català d'Oncologia, Brachytherapy, Barcelona, Spain. 2 Hospital Universitario de Navarra, Radiation Oncology, Pamplona, Spain. 3 Institut Català d'Oncologia, Medical Physics, Barcelona, Spain. 4 Institut Català